SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021)
Por:
Capdevila, J, Gomez, MA, Guillot, M, Paez, D, Pericay, C, Safont, MJ, Tarazona, N, Vera, R, Vidal, J, Sastre, J
Publicada:
1 abr 2022
Ahead of Print:
1 mar 2022
Resumen:
The management of localized rectal cancer requires a multidisciplinary approach to optimize outcomes, reduce morbidity and prevent under or overtreatments. While early stages may obtain benefit of local resections without any additional therapies, locally advanced rectal cancer becomes a challenge defining the better sequential strategy of surgery, radiotherapy and chemotherapy. The latest results of international phase III studies have positioned the total neoadjuvant therapy as a potential new standard of care in high risk rectal cancers, however, the best schedule is still not well defined.
Filiaciones:
Capdevila, J:
Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain
Gomez, MA:
Hosp Univ Reina Sofia, Dept Med Oncol, IMIBIC, CIBERONC, Cordoba, Spain
Guillot, M:
Hosp Univ Son Espases, Dept Med Oncol, Palma De Mallorca, Spain
Paez, D:
Hosp Santa Creu & Sant Pau, Dept Med Oncol, U705, CIBERER, Barcelona, Spain
Pericay, C:
Hosp Univ Mutua Terrassa, Dept Med Oncol, Terrassa, Spain
Safont, MJ:
Univ Valencia, Consorcio Hosp Gen Univ Valencia, Dept Med Oncol, CIBERONC, Valencia, Spain
Tarazona, N:
Univ Valencia, Incl Biomed Res Inst, Dept Med Oncol, Valencia, Spain
Inst Salud Carlos III, CIBERONC, Madrid, Spain
Vera, R:
Hosp Univ Navarra, Dept Med Oncol, Pamplona, Spain
IDISNA, Navarrabiomed, Pamplona, Spain
Vidal, J:
Hosp del Mar IMIM, Dept Med Oncol, CIBERONC, Barcelona, Spain
Sastre, J:
Hosp Univ Clin San Carlos, Dept Med Oncol, Madrid, Spain
hybrid
|